ATE522502T1 - Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthält - Google Patents

Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthält

Info

Publication number
ATE522502T1
ATE522502T1 AT03811921T AT03811921T ATE522502T1 AT E522502 T1 ATE522502 T1 AT E522502T1 AT 03811921 T AT03811921 T AT 03811921T AT 03811921 T AT03811921 T AT 03811921T AT E522502 T1 ATE522502 T1 AT E522502T1
Authority
AT
Austria
Prior art keywords
halogenated
hydrogen
respiratory diseases
lower alkyl
active ingredient
Prior art date
Application number
AT03811921T
Other languages
English (en)
Inventor
Yasushige Akada
Kazuyuki Matsuura
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Application granted granted Critical
Publication of ATE522502T1 publication Critical patent/ATE522502T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03811921T 2002-11-25 2003-11-25 Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthält ATE522502T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002341251 2002-11-25
PCT/JP2003/015005 WO2004048326A1 (ja) 2002-11-25 2003-11-25 4−ヒドロキシピペリジン誘導体を有効成分とする呼吸器疾患治療剤

Publications (1)

Publication Number Publication Date
ATE522502T1 true ATE522502T1 (de) 2011-09-15

Family

ID=32375845

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03811921T ATE522502T1 (de) 2002-11-25 2003-11-25 Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthält

Country Status (7)

Country Link
US (1) US7494987B2 (de)
EP (1) EP1568688B1 (de)
JP (1) JP4544999B2 (de)
AT (1) ATE522502T1 (de)
AU (1) AU2003302416A1 (de)
CA (1) CA2507509A1 (de)
WO (1) WO2004048326A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008179541A (ja) * 2005-05-02 2008-08-07 Mochida Pharmaceut Co Ltd 神経因性疼痛治療薬
NZ569532A (en) 2006-01-04 2010-11-26 Cipla Ltd Process and intermediate for preparation of donepezil
AR065816A1 (es) * 2007-03-26 2009-07-01 Theramex Regimen anticonceptivo oral
EP2448938B9 (de) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinone als pi3k-hemmer
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
JP5781537B2 (ja) * 2009-12-23 2015-09-24 メディシス ファーマシューティカル コーポレイション ヒスタミンh4受容体アンタゴニストとしてのアミノアルキルピリミジン誘導体
EP2558463A1 (de) 2010-04-14 2013-02-20 Incyte Corporation Kondensierte derivate als i3-hemmer
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン
US9108984B2 (en) * 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) * 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
MX389479B (es) 2011-09-02 2025-03-20 Incyte Holdings Corp Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k)
CA2861804C (en) * 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CN107223125B (zh) * 2014-09-17 2019-09-27 赛科理音医疗有限公司 sGC刺激剂
SG10201912302VA (en) 2015-02-27 2020-02-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
IL278889B2 (en) 2018-06-01 2025-11-01 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
CN115215787A (zh) * 2021-04-19 2022-10-21 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508724A (en) * 1984-02-03 1985-04-02 A. H. Robins Company, Inc. Aryloxymethylpyrrolidinols and piperidinols having antidepressant, antiarrhythmic or hypotensive activity
MY104343A (en) * 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
AU655840B2 (en) 1991-07-17 1995-01-12 Pfizer Inc. 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents
US5696267A (en) * 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
JP2001507673A (ja) * 1996-10-28 2001-06-12 シェーリング コーポレイション ニューロキニンアンタゴニストとしての置換アリールアルキルアミン
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
JP2000103782A (ja) * 1998-07-31 2000-04-11 Kyorin Pharmaceut Co Ltd 環状アミン誘導体及びその製造方法
AU3676000A (en) * 1999-04-09 2000-11-14 Mochida Pharmaceutical Co., Ltd. 4-hydroxypiperidine derivatives having antiarrhythmic effect
CA2369695A1 (en) * 1999-04-09 2000-10-19 Manabu Itoh Agent for treating neuropathic pain
EP1318988A2 (de) 2000-09-11 2003-06-18 Sepracor, Inc. Liganden für monoamin rezeptoren und transporter, und verwendungsmethoden dafür (neurotransmission)
JP2005097120A (ja) * 2000-10-06 2005-04-14 Mochida Pharmaceut Co Ltd 4−ヒドロキシピペリジン誘導体の非潮解性塩
CA2448509A1 (en) * 2001-05-25 2002-12-05 Mochida Pharmaceutical Co., Ltd. 4-hydroxypiperidine derivatives having analgesic activity

Also Published As

Publication number Publication date
JP4544999B2 (ja) 2010-09-15
EP1568688B1 (de) 2011-08-31
AU2003302416A1 (en) 2004-06-18
EP1568688A4 (de) 2008-12-17
US7494987B2 (en) 2009-02-24
JPWO2004048326A1 (ja) 2006-03-23
EP1568688A1 (de) 2005-08-31
WO2004048326A1 (ja) 2004-06-10
CA2507509A1 (en) 2004-06-10
US20060040985A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
EP1568688A4 (de) Therapeutisches mittel gegen atemwegserkrankungen, das ein 4-hydroxypiperidinderivat als wirkstoff enthält
BR0316586A (pt) Derivados de diidropirano indol-3, 4-dione e derivados de 3-ácido oxoacético 2-hidroximetilindol substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
DE69530690D1 (de) Benzoheterocyclische derivate verwendbar als vasopressin- oder oxytocin-modulatoren
ATE475652T1 (de) Chinazolinderivate
NO20021401L (no) Kinazolinforbindelser og farmasöytiske preparater som inneholder slike forbindelser
DE69331843D1 (de) Xanthine-Derivate als Antidepressiva
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
DE60303954D1 (de) Chinolyl-propylpiperidinderivate und deren verwendung als antimikrobielle wirkstoffe
ATE411317T1 (de) Indol-3-carbinol metaboliten als chemotherapeutische und chemopräventive wirkstoffen
AR045959A1 (es) Derivados de pirazolo- e imidazo-pirimidina
NO20064297L (no) Aminoalkoholforbindelse
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
KR970069990A (ko) 페닐렌 유도체
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
GEP20053626B (en) Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
NO20064706L (no) Thyroid reseptor agonister
DE60202682D1 (de) Chinoline derivate und ihre anwendung als antitumor agentien
ATE326451T1 (de) Chinazolin derivate und therapeutische verwendungen davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties